177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response

被引：0
|
作者：
Kambiz Rahbar
Martin Bögemann
Hojjat Ahmadzadehfar
机构：
[1] University Hospital of Muenster,Department of Nuclear Medicine
[2] University Hospital of Muenster,Department of Urology
[3] University Hospital of Bonn,Department of Nuclear Medicine
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2017年 / 44卷
关键词：
PSMA-617; Radioligand therapy; mCRPC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：166 / 167
页数：1
相关论文
共 50 条
  • [1] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
    Rahbar, Kambiz
    Boegemann, Martin
    Ahmadzadehfar, Hojjat
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 166 - 167
  • [2] 177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response Reply
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Tripathi, Madhavi
    Bal, Chandrasekhal
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (01) : 168 - 169
  • [3] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [4] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [5] Safety and efficacy of 177lu-PSMA-617 radioligand therapy in patients with mCRPC: A multicenter study.
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Kratochwil, Clemens
    Baum, Richard P.
    Schmidt, Matthias
    Pfestroff, Andreas
    Prasad, Vikas
    Heinzel, Aelxander
    Ruf, Juri
    Eveslage, Maria
    Boegemann, Martin
    Fendler, Wolfgang
    Krause, Bernd J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [6] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [7] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [8] Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Kiess, Ana
    Lukens, J. Nicholas
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2025, 15 (01) : 14 - 18
  • [9] Renal Function after Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, Christina Nguyen
    Happel, Christian
    Davis, Karen
    Groener, Daniel
    Mader, Nicolai
    Mandel, Philipp
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [10] A Hangover Under 177Lu-PSMA-617 Therapy
    Poterszman, Nathan
    Somme, Laura
    Bund, Caroline
    Hutt, Emilie
    Somme, Francois
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (06) : 582 - 583
12345